Compositions and methods for recombinant aav production
AssigneeREGENXBIO Inc.
InventorsJie LI, Ping LIU
Life of this patent
Estimating the term…
Abstract
Provided herein are host cells suitable for use in the production of recombinant AAV particles and polypeptides. Also provided herein are methods for producing rAAV particles and polypeptides.
Claims78
A recombinant cell capable of producing rAAV, wherein the cell comprises at least one modification that reduces or eliminates the activity of at least one endogenous gene or gene product in the apoptosis signaling pathway.
A cell bank comprising a plurality of cells, wherein the cells comprise at least one modification that reduces or eliminates the activity of at least one endogenous gene or gene product in the apoptosis signaling pathway.
A cell culture comprising a plurality of cells capable of producing rAAV, wherein the cells comprise at least one modification that reduces or eliminates the activity of at least one endogenous gene or gene product in the apoptosis signaling pathway.
A method of producing rAAV particles, comprising
- a) providing a cell culture comprising a plurality of cells capable of producing rAAV;
- and
- b) maintaining the cell culture under conditions that allow production of the rAAV particles,
- wherein the cells comprise at least one modification that reduces or eliminates the activity of at least one endogenous gene or gene product in the apoptosis signaling pathway.
A method for producing rAAV particles, comprising culturing a cell capable of producing rAAV particles under conditions that allow the production of the rAAV particles, wherein the cell comprises at least one modification that reduces or eliminates the activity of at least one endogenous gene or gene product in the apoptosis signaling pathway.
A method of increasing the production of rAAV particles, comprising
- a) providing a cell culture comprising a plurality of cells capable of producing rAAV;
- and
- b) maintaining the cell culture under conditions that allow production of the rAAV particles,
- wherein the cell comprises at least one modification that reduces or eliminates the activity of at least one endogenous gene or gene product in the apoptosis signaling pathway.
A method of increasing the production of rAAV particles, comprising culturing a cell capable of producing rAAV particles under conditions that allow the production of the rAAV particles, wherein the cell comprises at least one modification that reduces or eliminates the activity of at least one endogenous gene or gene product in the apoptosis signaling pathway.
A method of producing rAAV particles, comprising
- a) providing a cell culture comprising a plurality of cells;
- b) introducing into the cells one or more polynucleotides encoding at least one of
- i. an rAAV genome to be packaged,
- ii. adenovirus helper functions necessary for packaging,
- iii. an AAV rep protein sufficient for packaging, and
- iv. an AAV cap protein sufficient for packaging;
- and
- c) maintaining the cell culture under conditions that allow production of the rAAV particles,
- wherein the cells comprise at least one modification that reduces or eliminates the activity of at least one endogenous gene or gene product in the apoptosis signaling pathway.
A method of increasing the production of rAAV particles, comprising
- a) providing a cell culture comprising a plurality of cells;
- b) introducing into the cells one or more polynucleotides encoding at least one of
- i. an rAAV genome to be packaged,
- ii. adenovirus helper functions necessary for packaging,
- iii. an AAV rep protein sufficient for packaging, and
- iv. an AAV cap protein sufficient for packaging;
- and
- c) maintaining the cell culture under conditions that allow production of the rAAV particles
- wherein the cells comprise at least one modification that reduces or eliminates the activity of at least one endogenous gene or gene product in the apoptosis signaling pathway.
Dependencies are inferred from the claim text.